» Articles » PMID: 29124088

Considerations and Code for Partial Volume Correcting [F]-AV-1451 Tau PET Data

Overview
Journal Data Brief
Date 2017 Nov 11
PMID 29124088
Citations 160
Authors
Affiliations
Soon will be listed here.
Abstract

[F]-AV-1451 is a leading tracer used with positron emission tomography (PET) to quantify tau pathology. However, [F]-AV-1451 shows "off target" or non-specific binding, which we define as binding of the tracer in unexpected areas unlikely to harbor aggregated tau based on autopsy literature [1]. Along with caudate, putamen, pallidum and thalamus non-specific binding [2], [3], we have found binding in the superior portion of the cerebellar gray matter, leading us to use inferior cerebellar gray as the reference region. We also addressed binding in the posterior portion of the choroid plexus. PET signal unlikely to be associated with tau also occurs in skull, meninges and soft tissue (see e.g. [4]). We refer to [F]-AV-1451 binding in the skull and meninges as extra-cortical hotspots (ECH) and find them near lateral and medial orbitofrontal, lateral occipital, inferior and middle temporal, superior and inferior parietal, and inferior cerebellar gray matter. Lastly, the choroid plexus also shows non-specific binding that bleeds into hippocampus. We are providing the code (http://www.runmycode.org/companion/view/2798) used to create different regions of interest (ROIs) that we then used to perform Partial Volume Correction (PVC) using the Rousset geometric transfer matrix method (GTM, [5]). This method was used in the companion article, "Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's Disease" ([6], DOI 10.1016/j.neuroimage.2017.05.058).

Citing Articles

Lower Network Functional Connectivity Is Associated With Higher Regional Tau Burden Among Those At-Risk of Alzheimer's Disease But Cognitively Unimpaired: Specific Patterns Based on Amyloid Status.

Ford J, Mohanty R, Westman E, Middleton L Res Sq. 2025; .

PMID: 39975923 PMC: 11838755. DOI: 10.21203/rs.3.rs-5820051/v1.


Amyloid-β and tau deposition in traumatic brain injury: a study of Vietnam War veterans.

de Bruin H, Groot C, Kamps S, Vijverberg E, Steward A, Dehsarvi A Brain Commun. 2025; 7(1):fcaf009.

PMID: 39845735 PMC: 11752645. DOI: 10.1093/braincomms/fcaf009.


Cognitive aging outcomes are related to both tau pathology and maintenance of cingulate cortex structure.

Pezzoli S, Giorgio J, Chen X, Ward T, Harrison T, Jagust W Alzheimers Dement. 2025; 21(2):e14515.

PMID: 39807642 PMC: 11848174. DOI: 10.1002/alz.14515.


Enhancing Amyloid PET Quantification: MRI-Guided Super-Resolution Using Latent Diffusion Models.

Shah J, Che Y, Sohankar J, Luo J, Li B, Su Y Life (Basel). 2025; 14(12.

PMID: 39768288 PMC: 11678505. DOI: 10.3390/life14121580.


Multimodal neuroimaging biomarkers and subtle cognitive decline in a population-based cohort without dementia.

Weinstein A, Fang F, Chang C, Cohen A, Lopresti B, Laymon C J Alzheimers Dis. 2024; 103(2):570-581.

PMID: 39702989 PMC: 11798718. DOI: 10.1177/13872877241303926.


References
1.
Lowe V, Curran G, Fang P, Liesinger A, Josephs K, Parisi J . An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016; 4(1):58. PMC: 4906968. DOI: 10.1186/s40478-016-0315-6. View

2.
Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

3.
Rousset O, Ma Y, Evans A . Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998; 39(5):904-11. View

4.
Maass A, Landau S, Baker S, Horng A, Lockhart S, La Joie R . Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Neuroimage. 2017; 157:448-463. PMC: 5814575. DOI: 10.1016/j.neuroimage.2017.05.058. View

5.
Scholl M, Lockhart S, Schonhaut D, ONeil J, Janabi M, Ossenkoppele R . PET Imaging of Tau Deposition in the Aging Human Brain. Neuron. 2016; 89(5):971-982. PMC: 4779187. DOI: 10.1016/j.neuron.2016.01.028. View